Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata referenced Tenax Therapeutics, but filing text identifies Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended July 31, 1998.
Status: Development Stage Company in pre-clinical trial stage.
Shares Outstanding: 50,729,302 shares of common stock.
Key Financial Metrics
| Metric | Three Months Ended July 31, 1998 | Three Months Ended July 31, 1997 | Accumulated (Development Stage) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(227,662) | $(214,107) | $(9,795,826) |
| Net Loss Per Share | $(0.005) | $(0.004) | N/A |
| Cash and Equivalents (End of Period) | $455,785 | $15,877 | N/A |
| Working Capital | $(1,197) | N/A | N/A |
| Total Assets | $705,020 | N/A | N/A |
| Total Liabilities | $581,129 | N/A | N/A |
| Notes Payable | $103,021 | N/A | N/A |
Material Changes vs. Prior Period
- Expenses: Total expenses for the quarter were $234,290, an increase from $214,221 in the prior year quarter.
- Research & Development: Decreased to $24,982 from $46,365 due to reduced personnel and supply purchases.
- General & Administrative: Increased to $203,388 from $167,064 due to additional personnel and legal fees.
- Liquidity: Cash balance increased significantly to $455,785 from $15,877 in the prior year, driven by financing activities including proceeds from the sale of common stock ($6.1M) and convertible debentures ($811k).
- Net Loss: Quarterly net loss increased slightly to $227,662 from $214,107.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has accumulated losses of nearly $9.8 million and a working capital deficit.
- Capital Needs: Significant additional financing is required to complete pre-clinical testing and proceed to FDA-required Phase I, II, and III human trials. Management is pursuing strategic alliances and joint ventures.
- Regulatory Risk: No assurance can be given that FDA approval will be granted once applied for.
- Management Changes: Leland C. Clark, Jr., Ph.D., resigned as an officer and director, replaced by Howard Jones, Ph.D.
- Contingencies: The company has employment agreements with future commitments of $274,000 through February 2000. No material litigation is currently pending.
Investor Verification Checklist
- Verify the discrepancy between the metadata company name (Tenax Therapeutics) and the filing registrant (Synthetic Blood International, Inc.).
- Confirm the status of the "Going Concern" warning and the timeline for securing the necessary funding for clinical trials.
- Review the terms of the $811,000 in convertible debentures and $6.1M in stock sales to understand dilution risks.
- Assess the progress of pre-clinical trials and the likelihood of FDA approval given the lack of revenue history.
- Validate the $274,000 in committed employment contract obligations against current cash reserves.